COVID-19, SARS-CoV 2, Coronavirus Infection
Conditions
Keywords
Melatonin intravenous, Placebo intravenous, ICU patients, COVID-19
Brief summary
There is an urgent need to evaluate effective treatments for COVID-19 patients. Melatonin has significant anti-inflammatory and antioxidant properties and it lacks of side-effects. This randomized controlled trial seeks to evaluate the efficacy of intravenous melatonin in reducing mortality in Covid-19 patients in the ICUs.
Detailed description
ICU COVID-19 patients show high risk of death mainly due to sepsis and respiratory disfunction. Prevention of these critical conditions is mandatory to reduce mortality and to improve patient's outcome. Melatonin is an endogenous hormone involved not only in circadian rhythm control, but also in the cell protection due to its outstanding anti-inflammatory and antioxidative effects. High doses of melatonin have shown high efficacy against bacterial (sepsis) and viral infections. Melatonin is a safe product that consistently has shown lack of side-effects when it is administered to humans. SARS-CoV 2 infection may yield severe forms of the disease that require the patients admission to the ICU. These patients may develop an excessive inflammatory response and a burst of free radicals, constituting the major cause of death in these subjects. Our hypothesis is that high doses of melatonin intravenously administered to COVID-19 ICU patients might reach enough blood levels able to prevent/counteract the developing of sepsis and the production of free radicals, reducing mortality and hospital stay.
Interventions
DRUGMelatonin intravenous
7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
Sponsors
Hospital Universitario La Paz
Instituto de Investigación Hospital Universitario La Paz
Pharmamel S.L.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
phase II, single-center, double-blind, randomized placebo-controlled trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient, family member or legal guardian has provided written Informed Consent. * Age ε 18 years. * Confirmed SARS-CoV-2 infection with compatible symptoms AND a positive RT-PCR. * Admission to the ICU with acute hypoxemic respiratory failure attributed to SARS-CoV-2 infection. * ICU length of stay of less than 7 days prior to randomization with or without MV and without signs of improvement in respiratory failure (MURRAY score at randomization greater or equal to the MURRAY score at ICU admission).
Exclusion criteria
* Participant in a different COVID-19 study in which the study drug is under clinical development and hasn't been previously authorized for commercialization. * Liver enzymes \> 5 times the upper normal range. * Chronic kidney disease with GFR \< 30 mL/min/1.73 m2 (stage 4 or greater) or need for hemodialysis. * Pregnancy. A pregnancy test will be performed on every woman younger than 55 years of age prior to inclusion. * Terminal surgical or medical illness. * Autoimmune disease. * Any patient condition that can prevent the study procedures to be carried out at the treating physician's judgement.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | one month | Mortality in each study group represented in frequency and time-to-event at day 28 after randomization |
Countries
Spain
Outcome results
None listed